Optimization of approaches to the management of adult patients with severe atopic dermatitis: analysis of real clinical practice outcomes
- Authors: Fomina D.S.1,2, Serdotetskova S.A.1, Chernov A.A.1,3, Lebedkina M.S.2, Nurtazina A.I.1,2, Gadzhieva M.K.1, Mukhina O.A.1, Bobrikova E.N.1
-
Affiliations:
- City Clinical Hospital №52
- Sechenov First Moscow State Medical University (Sechenov University)
- Russian Medical Academy of Continuous Professional Education
- Issue: Vol 23, No 8 (2021)
- Pages: 654-661
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/97102
- DOI: https://doi.org/10.26442/20751753.2021.8.201115
- ID: 97102
Cite item
Full Text
Abstract
Atopic dermatitis (AD) is a multifactorial genetically determined immune-mediated skin disease. It is difficult to treat and significantly affects patients’ quality of life. The development of an integrated approach focusing on atopic multimorbidity, implementation of validated control tools and distinction of clinical parameters specific for different phenotypes of severe forms of disease is especially relevant to patients resistant to standard therapy techniques. Dupilumab, a biologic, is approved for the treatment of the resistant group of patients with moderate to severe AD in the Russian Federation. Dupilumab inhibits the functions of two key cytokines of T2-mediated inflammation – IL-4 and IL-13. The article presents personal experience of the authors concerning individual approach to the choice of therapy for the management of this cohort of patients in routine clinical practice. The disease aggravating criteria were determined, which are fundamental for the formation of individual patient portrait for the biologic (dupilumab) treatment for severe AD.
Full Text
##article.viewOnOriginalSite##About the authors
Daria S. Fomina
City Clinical Hospital №52; Sechenov First Moscow State Medical University (Sechenov University)
Author for correspondence.
Email: daria_fomina@mail.ru
ORCID iD: 0000-0002-5083-6637
Cand. Sci. (Med.)
Russian Federation, Moscow; MoscowSofya A. Serdotetskova
City Clinical Hospital №52
Email: darklynx813@gmail.com
ORCID iD: 0000-0001-8472-1152
allergist-immunologist
Russian Federation, MoscowAnton A. Chernov
City Clinical Hospital №52; Russian Medical Academy of Continuous Professional Education
Email: sbornay1med@yandex.ru
ORCID iD: 0000-0001-6209-387X
therapist
Russian Federation, Moscow; MoscowMarina S. Lebedkina
Sechenov First Moscow State Medical University (Sechenov University)
Email: marina.ivanova0808@yandex.ru
ORCID iD: 0000-0002-9545-4720
Clinical Resident
Russian Federation, MoscowAsel Iu. Nurtazina
City Clinical Hospital №52; Sechenov First Moscow State Medical University (Sechenov University)
Email: asel26nurtazina@mail.ru
ORCID iD: 0000-0002-2337-3307
allergist-immunologist
Russian Federation, Moscow; MoscowMirada K. Gadzhieva
City Clinical Hospital №52
Email: mirada05@mail.ru
ORCID iD: 0000-0001-8899-0851
allergist-immunologist
Russian Federation, MoscowOlga A. Mukhina
City Clinical Hospital №52
Email: mukhina.a.o@gmail.com
ORCID iD: 0000-0002-3794-4991
allergist-immunologist
Russian Federation, MoscowElena N. Bobrikova
City Clinical Hospital №52
Email: elena.bobrikova.69@mail.ru
ORCID iD: 0000-0002-6534-5902
Head of the Consultative and Diagnostic Department of the Center for Allergology and Immunology
Russian Federation, MoscowReferences
- Атопический дерматит. Проект клинических рекомендаций. 2020 г. РААКИ. Режим доступа: https://raaci.ru/dat/pdf/KR/atopic_dermatitis_2020.pdf. Ссылка активна на 26.08.2021 [Atopicheskii dermatit. Proekt klinicheskikh rekomendatsii. 2020 g. RAAKI. Available at: https://raaci.ru/dat/pdf/KR/atopic_dermatitis_2020.pdf. Accessed: 26.08.2021 (in Russian)].
- Silverberg JI. Public Health Burden and Epidemiology of Atopic Dermatitis. Dermatol Clin. 2017;35(3):283-9. doi: 10.1016/j.det.2017.02.002
- Esnault S, Benbernou N, Lavaud F, et al. Differential spontaneous expression of mRNA for IL-4, IL-10, IL-13, IL-2 and interferongamma (IFN-gamma) in peripheral blood mononuclear cells (PBMC) from atopic patients. Clin Exp Immunol. 1996;103(1):111-8.
- Werner Y, Lindberg M. Transepidermal water loss in dry and clinically normal skin in patients with atopic dermatitis. Acta Derm Venereol. 1985;65(2):102-5.
- Jujo K, Renz H, Abe J, et al. Decreased interferon gamma and increased interleukin-4 production in atopic dermatitis promotes IgE synthesis. J Allergy Clin Immunol. 1992;90(3 Pt. 1):323-31.
- Kaminishi K, Soma Y, Kawa Y, et al. Flow cytometric analysis of IL-4, IL-13 and IFN-gamma expression in peripheral blood mononuclear cells and detection of circulating IL-13 in patients with atopic dermatitis provide evidence for the involvement of type 2 cytokines in the disease. J Dermatol Sci. 2002;29(1):19-25.
- Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2009;124(3 Suppl. 2):R7-12.
- Wollenberg A, Wagner M, Gunther S, et al. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol. 2002;119(5):1096-102.
- Howell MD, Wollenberg A, Gallo RL, et al. Cathelicidin deficiencypredisposes to eczema herpeticum. J Allergy Clin Immunol. 2006;117(4):836-41.
- Kerschenlohr K, Decard S, Przybilla B, et al. Atopy patch test reactions show a rapid influx of inflammatory dendritic epidermal cells (IDEC) in extrinsic and intrinsic atopic dermatitis patients. J Allergy Clin Immunol. 2003;111:869-74.
- Wollenberg A, Kraft S, Hanau D, et al. Immunomorphological and ultrastructural characterization of Langerhans cells and a novel, inflammatory dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema. J Invest Dermatol. 1996;106(3):446-53.
- Danso MO, Van Drongelen V, Mulder A, et al. TNF-alpha and Th2 cytokines induce atopic dermatitis-like features on epidermal differentiation proteins and stratum corneum lipids in human skin equivalents. J Invest Dermatol. 2014;134(7):1941-50.
- Van den Oord RA, Sheikh A. Filaggrin gene defects and risk of developing allergic sensitisation and allergic disorders: systematic review and meta-analysis. BMJ. 2009;339:b2433 doi: 10.1136/bmj.b2433
- Paller AS, Spergel JM, Mina-Osorio P, Irvine AD. The atopic march and atopic multimorbidity: Many trajectories, many pathways. J Allergy Clin Immunol. 2019;143(1):46-55. doi: 10.1016/j.jaci.2018.11.006
- Breiteneder H, Peng YQ, Agache I. Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma. Allergy. 2020;75(12):3039-68. doi: 10.1111/all.14582
- Belgrave DCM, Simpson A, Buchan IE, Custovic A. Atopic dermatitis and respiratory allergy: what is the link. Curr Dermatol Rep. 2015;4:221e227.
- Simpson EL. Comorbidity in atopic dermatitis. Curr Dermatol Rep. 2012;1:29-38.
- Brunner PM, Silverberg JI, Guttman-Yassky E, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol. 2017;137:18-25.
- Yaghmaie P, Koudelka CW, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol. 2013;131:428-33.
- Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019;143(1):1-11. doi: 10.1016/j.jaci.2018.10.032
- Mulick AR, Allen V, Williams HC, et al. Classifying atopic dermatitis: protocol for a systematic review of subtypes (phenotypes) and associated characteristics. BMJ Open. 2018;8(9):e023097. doi: 10.1136/bmjopen-2018-023097
- Bieber T, D'Erme AM, Akdis CA, et al. Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go? J Allergy Clin Immunol. 2017;139(4S):S58-64. doi: 10.1016/j.jaci.2017.01.008
- Salvador JF. Atopic Dermatitis in Adults: A Diagnostic Challenge. J Investig Allergol Clin Immunol. 2017;27(2):78-88. doi: 10.18176/jiaci.013
- Seegräber M, Srour J, Walter A, et al. Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol. 2018;11(5):467-74. doi: 10.1080/17512433.2018.1449642
- Tavecchio S, Angileri L, Pozzo GF, et al. Efficacy of Dupilumab on Different Phenotypes of Atopic Dermatitis: One-Year Experience of 221 Patients. J Clin Med. 2020;9(9):2684. doi: 10.3390/jcm9092684
- Simpson EL, Bieber T, Guttman-Yassky E, et al.Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016;375(24):2335-48. doi: 10.1056/NEJMoa1610020
- Silverberg JI, Yosipovitch G, Simpson EL. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. J Am Acad Dermatol. 2020;82(6):1328-36. doi: 10.1016/j.jaad.2020.02.060
- Deleuran M, Thaçi D, Beck LA. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol. 2020;82(2):377-88. doi: 10.1016/j.jaad.2019.07.074
- Cork MJ, Thaçi D, Eichenfield LF. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. Br J Dermatol. 2020;182(1):85-96. doi: 10.1111/bjd.18476
- Ariëns LFM, Bakker DS, van der Schaft J, et al. Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy. Ther Adv Chronic Dis. 2018;9(9):159-70. doi: 10.1177/2040622318773686
- Mortz CG, Andersen KE, Dellgren C, et al. Atopic dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence and comorbidities. Allergy. 2015;70(7):836-45. doi: 10.1111/all.12619
- Arima K, Gupta S, Gadkari A, et al. Burden of atopic dermatitis in Japanese adults: Analysis of data from the 2013 National Health and Wellness Survey. J Dermatol. 2018;45(4):390-6. doi: 10.1111/1346-8138.14218
- Wan J, Mitra N, Hoffstad OJ, et al. Margolis Longitudinal atopic dermatitis control and persistence vary with timing of disease onset in children: A cohort study. J Am Acad Dermatol. 2019;81(6):1292-9. doi: 10.1016/j.jaad.2019.05.016
- Baum S, Porat S, Lyakhovitsky A, et al. Adult Atopic Dermatitis in Hospitalized Patients: Comparison between Those with Childhood-Onset and Late-Onset Disease. Dermatology. 2019;235(5):365-71. doi: 10.1159/000499708
- Jo CE, Georgakopoulos JR, Ladda M, et al. Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate to severe atopic dermatitis in clinical practice: A retrospective cohort study. J Am Acad Dermatol. 2020;82(6):1530-2. doi: 10.1016/j.jaad.2020.02.029
- Armario-Hita JC, Pereyra-Rodriguez J, Silvestre JF, et al. Treatment of moderate-to-severe atopic dermatitis with dupilumab in real clinical practice: a multicentre, retrospective case series. Br J Dermatol. 2019;181(5):1072-74. doi: 10.1111/bjd.18041
- Cabanillas B, BrehlerA-C, Novak N. Atopic dermatitis phenotypes and the need for personalized medicine. Curr Opin Allergy Clin Immunol. 2017;17(4):309-15. doi: 10.1097/ACI.0000000000000376
- Fernández-Soto R, Navarrete-Rodríguez EM, Del-Rio-Navarro BE, et al. Allergy: Pattern of sensitization over the past 11 years. Allergol Immunopathol (Madr). 2018;46(6):557-64. doi: 10.1016/j.aller.2018.01.005
- Crameri R, Weichel M, Flückiger S, et al. Fungal allergies: A yet unsolved problem. Chem Immunol Allergy. 2006;91:121-33.
- Hamilos DL. Chronic rhinosinusitis: Epidemiology and medical management. J Allergy Clin Immunol. 2011;128:693-707.